Posts in Category: Cancer Treatment

Dr. Clay Siegall on Targeted Cancer Therapies

Dr. Clay Siegall has become a known figure in cancer treatment since founding his biotech firm Seattle Genetics, working with top researchers that develop targeted drug and therapy courses in an effort to improve these fields of research. Seattle Genetics started small but soon became an influential player in cancer research, and Dr. Clay Siegall intends for his firm to increase its standing as an authority in this field by better understanding how to tailor treatment for individual patients.

 

Dr. Siegall’s interest in medicine and technology guided his studies at the University of Maryland, and when a family member became ill he noted the changes in their health attributed to chemotherapy. This led him to consider alternatives to treatment.

 

Seattle Genetics is funded primary through sales of medication, and their currently awaiting FDA approval to put more into the market. Partnerships and licensing also helps by continuing to promote the Seattle Genetics brand while bringing in the funding necessary to deal with the expensive process of getting drugs approved by the FDA. But in the early days, Dr. Siegall relied on negotiating with and attracting investors. It was instrumental in getting the firm off the ground.

 

Moving forward, Dr. Siegall sees a bright future for Seattle Genetics. The hard work that has made his firm come this far, Dr. Siegall sees as an integral character trait of everyone working in this field.

 

About Dr. Clay Siegall:

 

Dr. Clay Siegall is an American geneticist and founder and CEO of Seattle Genetics. After receiving his Ph.D. in Genetics from George Washington University. Dr. Siegall served as a member of the National Cancer Institute and the National Institutes of Health between 1988 and 1991 before going on to join Bristol-Myers Squibb Pharmaceutical Research Institute until 1997.

 

In 1998, Dr. Siegall co-founded Seattle Genetics, a biomedical firm that focuses on researching and developing cancer treatment alternatives to chemotherapy where he serves as President, Chief Executive Officer, and Chairman of the Board of Directors. As an authority in the field, Dr. Siegall has been instrumental in raising investment in the company and has secured more than $675 million in public and private funds. In 2011 their antibody medication ADCETRIS was granted accelerated approval by the FDA.